drugset / Trial / NCT06747949

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949

Phase 3 Recruiting 844 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Timeline

Start
2025-02-25
Primary completion
2029-12-11
Completion
2029-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dazodalibep Protein / enzyme biologic Intravenous

Indications